# Tesamorelin vs Sermorelin: Structure, Stability, Evidence

> Tesamorelin vs sermorelin: a full-length GHRH(1-44) analogue with DPP-IV resistance versus the truncated GHRH(1-29) fragment. Structure, stability, and the evidence base compared. Cited.

Two GHRH analogues, different in length and stability — the full-length DPP-IV-resistant molecule against the truncated fragment, compared from the published record.

## In plain English

When people ask about tesamorelin vs sermorelin, the short answer is that both are lab-made versions of GHRH (the brain's "make growth hormone" signal), but they are built differently. Sermorelin is a short fragment — the first 29 amino acids. Tesamorelin is the full 44-amino-acid chain with an extra chemical cap that stops the body from breaking it down quickly. The practical difference: tesamorelin lasts longer in the blood, and it is the one with large Phase 3 trials behind it. This page compares structure, stability, and evidence — it does not recommend either.

## Structure: full-length versus truncated

Tesamorelin is a stabilized full-length analogue of human GHRH(1-44) — the complete 44-residue sequence — carrying a trans-3-hexenoic-acid group on its N-terminus [11]. Sermorelin, by contrast, is the truncated GHRH(1-29) fragment: the first 29 amino acids, which retain the receptor-binding activity of the parent hormone in a shorter molecule.

Both bind the same GHRH receptor on pituitary somatotrophs and prompt the body to release its own growth hormone. The structural difference is length and the N-terminal modification, and that difference is the whole basis of the stability contrast below [12].

## Stability: DPP-IV resistance

The defining contrast is what happens to each molecule in the bloodstream. Native GHRH — and unmodified fragments — are rapidly cleaved by DPP-IV, an enzyme that inactivates them within minutes [11]. Tesamorelin's N-terminal trans-3-hexenoyl group blocks that cleavage, extending plasma activity relative to native GHRH [11].

This is the engineering rationale tesamorelin was built around. A clinical review describes it specifically as a stabilized full-length GHRH(1-44) analogue distinct from the truncated GHRH(1-29) class, whose N-terminal modification confers DPP-IV resistance [11]. The stabilized design is why a short-half-life peptide can still be dosed once daily and sustain a downstream IGF-1 effect.

## Evidence base

The two compounds sit at very different points on the evidence curve. Tesamorelin carries an extensive randomized record in HIV-associated lipodystrophy: two pivotal Phase 3 trials, a JAMA hepatic-fat RCT, a dedicated type-2-diabetes safety trial, and a 2026 five-RCT meta-analysis [1][3][15]. It is FDA-approved (NDA 022505, 2010) for that single indication [5].

A broader review frames tesamorelin within the GRF-analogue rationale — that growth-hormone-releasing-factor analogues may be better tolerated than recombinant growth hormone — and summarizes the Phase III evidence for visceral-fat reduction with a good safety profile, while noting other potential indications appeared less promising [12]. This page compares the molecules; it is not a recommendation of either.

## What the comparison does not settle

Comparing structure and stability is not the same as comparing head-to-head outcomes. No large randomized trial directly pits tesamorelin against sermorelin on a shared endpoint in the literature digested here. Tesamorelin's evidence is anchored in HIV-associated lipodystrophy [1][2]; extending any comparison to general fat loss, anti-aging, or performance is off-label and unsupported by completed RCTs [12]. The structural and pharmacokinetic differences are well-characterized; comparative clinical superiority in a shared population is not.

---

Tesarx files the tesamorelin record as a flat, hard-bordered data sheet — every visceral-fat and IGF-1 figure logged straight to its study, the lone HIV-lipodystrophy approval and the off-label edge ruled in plain view; an exposed-document digest, never a clinic, a pharmacy, or a prescription.